Hereditary Autoinflammatory Diseases: Clinical Trials

26 trials for Hereditary Autoinflammatory Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 5 recruiting, 2 not yet recruiting, 2 terminated. 26 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 326Completed 17, Recruiting 5, Not yet recruiting 2, Terminated 2
Phase 21Completed 1

Follow Hereditary Autoinflammatory Diseases: new trials by email Literature Review of Hereditary Autoinflammatory Diseases trials Research Report on Hereditary Autoinflammatory Diseases

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
RPH-104 - Familial Mediterranean Fever, FMF
Phase 3Not yet recruitingR-Pharm182026-12-012026-10-19
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
Corticosteroids + Rivaroxaban, Corticosteroids alone - Behcet Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1342025-06-242026-04-23
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
Placebo plus immunosuppression, Rivaroxaban plus immunosupression - Behcet Disease, Behcet Disease and Vascular Involvement
Phase 3Not yet recruitingMarmara University1102025-04-302025-04-13
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
ANAKINRA - FMF
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris502024-06-042025-06-25
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
Hemay005, Placebo - Behçet's Disease
Phase 3RecruitingGanzhou Hemay Pharmaceutical Co., Ltd1622023-11-132025-04-08
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Apremilast - Behçet's Disease, Juvenile Psoriatic Arthritis
Phase 3RecruitingAmgen482023-03-232026-11-04
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Apremilast, Placebo - Behçet Disease
Phase 3RecruitingAmgen602021-09-092026-07-24
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Infliximab, Cyclophosphamide - Behcet's Disease, Vasculitis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris532018-05-252023-07-03
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis
Phase 3CompletedPeking Union Medical College Hospital282017-06-302021-02-23
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Infliximab - Behcet Disease
Phase 3CompletedJanssen Korea, Ltd., Korea332015-07-222019-10-17
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
Apremilast, Placebo - Behçet's Syndrome
Phase 3CompletedAmgen2072014-12-302021-07-22
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
Phase 3CompletedNovartis Pharmaceuticals312014-11-032020-05-19
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
Placebo, Gevokizumab - Behcet's Disease Uveitis
Phase 3TerminatedXOMA (US) LLC42014-11-012015-12-29
Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
Kineret - Familial Mediterranean Fever
Phase 3CompletedSheba Medical Center252012-11-012024-04-02
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Phase 3CompletedNovartis Pharmaceuticals172012-01-162018-09-11
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
TA-650 - Behcet's Disease, Behcet Syndrome
Phase 3CompletedTanabe Pharma Corporation182012-01-012026-01-07
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Phase 3CompletedNovartis Pharmaceuticals172010-11-012017-03-29
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
canakinumab (company code: ACZ885D) - Cryopyrin Associated Periodic Syndrome
Phase 3CompletedNovartis Pharmaceuticals42010-08-012017-03-21
Phase III Study in Refractory Behcet's Disease
AIN457, Placebo - Behcet Disease
Phase 3CompletedNovartis Pharmaceuticals1182009-10-012015-08-31
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
canakinumab - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Phase 3CompletedNovartis Pharmaceuticals192009-10-012020-09-25

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Behcet Syndrome (13)  ·  Cryopyrin-Associated Periodic Syndromes (9)  ·  Multiple Pterygium Syndrome, Autosomal Dominant (5)  ·  Familial Mediterranean Fever (4)  ·  Uveitis (3)  ·  Arthritis, Juvenile (2)  ·  Oral Ulcer (2)  ·  Panuveitis (2)  ·  Uveitis, Posterior (2)  ·  Amyloidosis (1)  ·  Arthralgia (1)  ·  Arthritis, Rheumatoid (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Gastrointestinal Diseases (1)  ·  Genetic Diseases, Inborn (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26)  ·  Genetic Diseases, Inborn (25)  ·  Skin and Connective Tissue Diseases (23)  ·  Skin Diseases (22)  ·  Skin Diseases, Genetic (22)  ·  Skin Diseases, Vascular (22)  ·  Cardiovascular Diseases (13)  ·  Eye Diseases (13)  ·  Mouth Diseases (13)  ·  Stomatognathic Diseases (13)  ·  Uveal Diseases (13)  ·  Uveitis, Anterior (13)  ·  Vascular Diseases (13)  ·  Vasculitis (12)

Interventions

canakinumab (8)  ·  apremilast (3)  ·  Cyclosporine (2)  ·  Infliximab (2)  ·  Interferon alpha-2 (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Rivaroxaban (2)  ·  Adrenal Cortex Hormones (1)  ·  Cyclic Nucleotide Phosphodiesterases, Type 4 (1)  ·  Cyclophosphamide (1)  ·  Hemay005 (1)  ·  Immune Tolerance (1)  ·  Immunosuppression Therapy (1)  ·  Pharmaceutical Preparations (1)  ·  gevokizumab (1)

Sponsors

Novartis Pharmaceuticals (7)  ·  Amgen (3)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Novartis (2)  ·  Bellus Health Inc. - a GSK company (1)  ·  Ganzhou Hemay Pharmaceutical Co., Ltd (1)  ·  Janssen Korea, Ltd., Korea (1)  ·  Marmara University (1)  ·  Peking Union Medical College Hospital (1)  ·  R-Pharm (1)  ·  Regeneron Pharmaceuticals (1)  ·  Sheba Medical Center (1)  ·  Tanabe Pharma Corporation (1)  ·  University Hospital Tuebingen (1)  ·  XOMA (US) LLC (1)

Countries

France (12)  ·  Spain (8)  ·  United States (8)  ·  Germany (7)  ·  Turkey (Türkiye) (7)  ·  Israel (6)  ·  United Kingdom (6)  ·  Italy (5)  ·  Greece (4)  ·  Switzerland (4)  ·  Belgium (3)  ·  Canada (3)  ·  India (3)  ·  Japan (3)  ·  South Korea (3)

Top investigators

Avi Livneh, professor (1)  ·  Fatma Alibaz-Oner, Prof (1)  ·  Ina Koetter, MD (1)  ·  Kazuoki Kondo, MD (1)  ·  Mikhail Samsonov (1)  ·  Robert Evans, PharmD. (1)  ·  Shunsei Hirohata, MD (1)  ·  Toshifumi Hibi, MD (1)  ·  Yoshiaki Ishigatsubo, MD, Ph.D (1)  ·  Zhanguo Li, Doctor (1)

Results publications

PMID 31161734, PMID 17554116, PMID 18668535, PMID 19494217, PMID 21859692, PMID 22152723, PMID 23031624, PMID 23290985, PMID 23380020, PMID 24906637, PMID 27310969, PMID 27860460, PMID 31722152, PMID 35798511, PMID 36578194, PMID 37316690

NIH funding

2009 (2), 2014 (2), 2023 (2)